InsiderTrades.com logo
Trump said you could learn something from this man
From Wide Moat Research   |   Ad
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
Here’s everything you need to know.
Brian Joseph Lynch net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Brian Lynch Biography and Net Worth

SVP of Madrigal Pharmaceuticals
Brian J. Lynch has been at Madrigal since 2018. For 30 years before joining Madrigal, Mr. Lynch engaged in private practice and was a partner at the leading law firms headquartered in Washington, DC, Philadelphia and Silicon Valley (Hogan Lovells, Morgan Lewis and Cooley). His practice focused on value-enhancing M&A, equity and debt capital markets, and collaboration transactions and a broad range of representations for life sciences companies, including Madrigal. Mr. Lynch began his legal career at the Securities and Exchange Commission’s Division of Corporation Finance in Washington, DC.

What is Brian Joseph Lynch's net worth?

The estimated net worth of Brian Joseph Lynch is at least $4.76 million as of December 4th, 2023. Mr. Lynch owns 15,001 shares of Madrigal Pharmaceuticals stock worth more than $4,756,667 as of November 20th. This net worth estimate does not reflect any other assets that Mr. Lynch may own. Additionally, Mr. Lynch receives a salary of $763,750.00 as SVP at Madrigal Pharmaceuticals. Learn More about Brian Joseph Lynch's net worth.

How old is Brian Joseph Lynch?

Mr. Lynch is currently 62 years old. There are 5 older executives and no younger executives at Madrigal Pharmaceuticals. The oldest executive at Madrigal Pharmaceuticals is Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, President of Research & Development and Director, who is 72 years old. Learn More on Brian Joseph Lynch's age.

What is Brian Joseph Lynch's salary?

As the SVP of Madrigal Pharmaceuticals, Inc., Mr. Lynch earns $763,750.00 per year. The highest earning executive at Madrigal Pharmaceuticals is Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, President of Research & Development and Director, who commands a salary of $939,830.00 per year. Learn More on Brian Joseph Lynch's salary.

How do I contact Brian Joseph Lynch?

The corporate mailing address for Mr. Lynch and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Brian Joseph Lynch's contact information.

Has Brian Joseph Lynch been buying or selling shares of Madrigal Pharmaceuticals?

Brian Joseph Lynch has not been actively trading shares of Madrigal Pharmaceuticals during the last ninety days. Most recently, Brian Joseph Lynch sold 1,800 shares of the business's stock in a transaction on Monday, December 4th. The shares were sold at an average price of $218.87, for a transaction totalling $393,966.00. Following the completion of the sale, the senior vice president now directly owns 15,001 shares of the company's stock, valued at $3,283,268.87. Learn More on Brian Joseph Lynch's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 2 times. They purchased a total of 145,509 shares worth more than $29,933,517.51. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 193,584 shares worth more than $42,301,962.98. The most recent insider tranaction occured on November, 1st when Director Richard S Levy sold 5,000 shares worth more than $1,504,700.00. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 11/1/2024.

Brian Joseph Lynch Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2023Sell1,800$218.87$393,966.0015,001View SEC Filing Icon  
11/29/2023Sell4,000$199.19$796,760.0015,001View SEC Filing Icon  
1/3/2023Sell13,000$282.92$3,677,960.00View SEC Filing Icon  
12/23/2022Sell7,000$274.18$1,919,260.00View SEC Filing Icon  
See Full Table

Brian Joseph Lynch Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Brian Joseph Lynch's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $317.09
Low: $310.84
High: $323.99

50 Day Range

MA: $246.71
Low: $202.48
High: $354.85

2 Week Range

Now: $317.09
Low: $168.25
High: $368.29

Volume

277,156 shs

Average Volume

662,765 shs

Market Capitalization

$6.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Trump said you could learn something from this man
From Wide Moat Research   |   Ad
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
Here’s everything you need to know.